[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:malignant-peritoneal-effusion":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":35,"states":36},"Malignant Peritoneal Effusion",4,2,[8,16,22,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06016179","Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:28.549392Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05726747","QOL and Sarcopenia in Patients With Ascites",[],"2026-08-26T02:18:56.409949Z","2026-05-13T02:55:06.372714Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT07490626","At-Home Paracentesis for Women With Cancer-Related Malignant Ascites (Paracentesis)",[],"NOT_YET_RECRUITING","2026-08-26T02:17:33.807405Z","2026-05-05T02:43:28.738231Z",{"nct_id":30,"title":31,"phases":32,"status":26,"updated_at":33,"content_modified":34},"NCT07658196","TLR9 Immunotherapy for Peritoneal Carcinomatosis",[12],"2026-08-26T02:18:32.765187Z","2026-06-18T12:24:03.102969Z",[],[]]